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Abstract
Background: Selective cyclooxygenase (COX)-2 inhibitors elicit anti-proliferative responses in various
tumours, however the underlying anti-tumour mechanisms are unclear. Mutational inactivation of the
tumour suppressor p53 gene is frequent in malignant gliomas. The role of p53 mutation in the anti-tumour
responses of the selective COX-2 inhibitor celecoxib in human glioblastoma cells is unknown. In this study,
we used human glioblastoma cells with various p53 status; U87MG (with high and low p53 functional
levels), LN229 (functional p53) and U373MG (mutant p53) cells. Inhibition of p53 was achieved in U87MG
cells transfected with E6 oncoprotein (U87MG-E6) and treated with pifithrin-α, a reversible inhibitor of
p53 (U87MG-PFT). We investigated whether the anti-glioblastoma responses of celecoxib were p53-
dependent, and whether celecoxib induced DNA damage leading to p53-dependent G1 cell cycle arrest,
followed by autophagy or apoptosis.
Results: Our findings demonstrated that celecoxib concentration-dependently reduced glioblastoma cell
viability, following 24 and 72 hours of treatment. Inhibition of functional p53 in glioblastoma cells
significantly reduced the anti-proliferative effect of celecoxib. In U87MG cells, celecoxib (8 and 30 μM)
significantly induced DNA damage and inhibited DNA synthesis, corresponding with p53 activation.
Celecoxib induced G1-phase cell cycle arrest, accompanied with p21 activation in U87MG cells. Cell cycle
progression of U87MG-E6 and U87MG-PFT cells was not affected by celecoxib. In parallel, celecoxib
induced G1 cell cycle arrest in LN229 cells, but not in U373MG cells. Autophagy was induced by celecoxib
in U87MG and LN229 cells, as shown by the significantly greater population of acridine orange-stained cells
and increased levels of LC3-II protein (in comparison with non-treated controls). Celecoxib did not induce
significant autophagy in U87MG-PFT, U87MG-E6 and U373MG cells, which lack functional p53. Regardless
of p53 status, celecoxib caused no significant difference in apoptosis level of U87MG, U87MG-PFT,
U87MG-E6 and U373MG cells.
Conclusion: Our findings reveal that p53 increases human glioblastoma sensitivity to celecoxib.
Celecoxib inhibits glioblastoma cell viability by induction of DNA damage, leading to p53-dependent G1
cell cycle arrest and p53-dependent autophagy, but not apoptosis.
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Despite conventional therapy of surgical resection, radio-
therapy and chemotherapy, the median survival of malig-
nant glioma patients remain poor. Most patients with
glioblastoma multiforme survive less than 2 years after
diagnosis [1]. Therapeutic improvements are needed to
extend the survival of malignant glioma patients.
Cyclooxygenase (COX)-2, an isoform of COX which is the
rate-limiting enzyme in conversion of arachidonic acid
into prostaglandins, is inducible in the presence of
cytokines and growth factors during inflammation [2].
The importance of COX-2 in carcinogenesis and brain
tumour progression is highlighted by the detection of
COX-2 in brain tumours [3,4] and COX-2 overexpression
in gliomas associated with poor prognosis [5]. Targeting
COX-2 with selective COX-2 inhibitors (NS-398, SC-236
and celecoxib) has proven effective to reduce human
glioblastoma cell viability in vitro [4,6-9] and in rodent
models [6,9-11]. Celecoxib is the only selective COX-2
inhibitor approved by the FDA for adjuvant treatment of
patients with familial adenomatous polyposis.
The molecular events underlying the anti-tumour proper-
ties of COX-2 inhibitors are not fully understood. Several
mechanisms have been proposed in various tumour mod-
els. COX-2 inhibition by celecoxib induces G1 cell cycle
arrest, corresponding with activation of G1-phase cyclin-
CDK inhibitors, p21 and p27 [12-14]. Celecoxib activates
apoptotic proteins BAD, caspases and PARP, followed by
cell apoptosis and reduced tumour cell proliferation
[9,13-17]. Anti-tumour mechanisms of COX-2 inhibitors
also include inhibition of tumour angiogenesis [18], inhi-
bition of prostaglandin-induced immunosuppressive
activity [19] and increased DNA damage/reduced DNA
repair capacity [20]. Peroxidation of arachidonic acid into
prostaglandins by COX generates reactive oxygen species
and free radicals, which induce DNA damage and tumour-
igenicity [21]. Inhibition of COX by COX inhibitors aspi-
rin [22], nimesulide [23], rofecoxib and celecoxib [24]
protects DNA from oxidative damage by scavenging
hydroxyl radicals and superoxide in vitro in non-tumour
models. However, prevention of DNA damage by COX
inhibitors has not been reported in tumour cells. In con-
trast, aspirin significantly induces DNA damage of HT-29
human colon carcinoma [25], whereas celecoxib causes
DNA damage in MCa-35 murine mammary and A549
human lung cancer cells [26]. Whether COX-2 inhibitors
induce DNA damage in glioblastoma cells is unclear.
Mutational inactivation of the tumour suppressor gene
p53 (a regulator of cell growth and death) is frequently
found in human tumours, with p53 mutation/inactiva-
tion reported in 63–65% of high-grade gliomas [27].
Induction of DNA damage initiates a cascade of signalling
with p53 activation (phosphorylation at Ser 15 and Ser
20) and subsequent transcriptional activation of p53
response genes (including p21, GADD45, BAX, PUMA,
Bcl2 and NOXA), thus provoking cell cycle arrest and/or
apoptosis [28]. Genotoxic stress caused by DNA-damag-
ing agents also induce p53-dependent autophagy [29,30],
the type II programmed cell death characterised by the for-
mation of cytosolic double-membrane vesicles
(autophagosomes) that engulf cellular content by diges-
tion, when fused with lysosomes [31]. The mechanisms of
p53-dependent induction of autophagy are not fully
understood, but are thought to involve both the transcrip-
tion-independent functions (e.g. activation of the nutrient
energy sensor AMP kinase) and transcription-dependent
functions (e.g. upregulation of mTOR inhibitors PTEN
and TSC1, or p53-regulated autophagy and cell death
gene DRAM) [30,32]. Anti-tumour mechanisms by COX
inhibition have been shown to be either p53-dependent
[33,34] or p53-independent in various cancer and non-
cancer cells. The anti-proliferative mechanism of COX-2
inhibitors underpin by autophagy induction in tumours is
unclear. To date, only one recent report suggests that
celecoxib induces both autophagy and apoptosis, medi-
ated by P-glycoprotein independent of p53 mechanisms,
in hepatocellular carcinoma cells [35]. The role of p53 in
celecoxib-induced autophagy and celecoxib-induced anti-
proliferative responses clearly needs to be verified.
In this study, we investigated (a) whether the anti-prolif-
erative response induced by celecoxib was dependent on
the presence of functional p53 and b) whether celecoxib-
induced DNA damage resulted in p53-dependent G1 cell
cycle arrest, followed by apoptosis or autophagy. We stud-
ied the effect of celecoxib in human glioblastoma cells
with various p53 status; U87MG cells with high and low
levels of p53 [by both genetic (oncoprotein E6) and phar-
maceutical intervention (pifithrin-α)], LN229 (with wild
type p53 function despite a p53 mutation in the coding
sequence [36]) and U373MG (with mutant p53) cells.
Our findings show that the anti-proliferative sensitivity of
celecoxib is dependent on p53 in human glioblastoma
cells. We further demonstrate that celecoxib enhances gli-
oma cytotoxicity by induction of DNA damage and p53-
dependent G1 cell cycle arrest, followed by p53-dependent
autophagy but not apoptosis.
Results
Celecoxib concentration-dependently inhibited human 
glioblastoma cell viability, with enhanced anti-
proliferative response by the presence of functional p53
Celecoxib concentration-dependently reduced the viabil-
ity of human glioblastoma cells U87MG, which contains
wild-type p53 (Figure 1A–D). To determine whether the
anti-proliferative response to celecoxib was dependent on
p53, we first compared the effect of celecoxib on viability
of U87MG-E6 and U87MG cells. Viral oncoprotein E6
inhibits p53 function by abrogating specific DNA binding
and transactivation of p53, sequestering p53 into the cyto-Page 2 of 16
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Concentration-dependent response of celecoxib on viability of human glioblastoma cellsFigure 1
Concentration-dependent response of celecoxib on viability of human glioblastoma cells. Cells were treated with 
a series of celecoxib concentrations for 24 (A, C, E) and 72 (B, D, F) hours. In some cases, U87MG cells were pre-treated with 
PFT (25 μM) for 30 minutes prior to celecoxib treatment. Cell viability was measured by MTT assays and presented as absorb-
ance readings at 570 nm normalised against controls. Values are expressed as mean ± S.E.M (n = 3–10). *P < 0.05 significantly 
different between two concentration-dependent response curves (2-way ANOVA).
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p53 by oncoprotein E6 reduced the sensitivity of U87MG
cells to celecoxib, as shown by the enhanced U87MG-E6
cell viability following celecoxib treatment, compared
with non-transfected U87MG cells (Figure 1A–B). Follow-
ing 72 hours of celecoxib treatment, U87MG-E6 cells were
significantly more viable than U87MG cells (P < 0.05, Fig-
ure 1B). The prerequisite of p53 to protect U87MG cells
from the anti-proliferative effect of celecoxib was con-
firmed with U87MG cells treated with PFT (U87MG-PFT).
PFT-α inhibits p53 by reversibly blocking p53-transcrip-
tional activation [38]. Inhibition of p53 by PFT signifi-
cantly reduced sensitivity of U87MG cells to celecoxib,
with enhanced U87MG-PFT cell viability at 24 and 72
hours following celecoxib treatment, compared with
untreated U87MG cells (P < 0.05, Figure 1C–D).
The p53-dependent anti-proliferative response induced
by celecoxib was also shown in LN229 and U373MG
glioblastoma cells. Celecoxib (24 and 72 hours treatment)
inhibited viability of LN229 and U373MG cells in a con-
centration-dependent manner (Figure 1E–F). At 72 hours
of celecoxib treatment, U373MG cells (with mutant p53)
were significantly more viable than LN229 cells (with
functional p53; P < 0.05, Figure 1F). These results parallel
the enhanced anti-proliferative responses of celecoxib in
U87MG cells (high level of functional p53), compared
with U87MG-E6 and U87MG-PFT (low functional level of
p53), thus verifying a p53-dependent anti-proliferative
response induced by celecoxib. In subsequent experi-
ments, we tested the effect of celecoxib at 8 μM, a concen-
tration equivalent to human plasma concentration
following consumption of 800 mg/kg celecoxib daily (the
FDA approved dosage for familial adenomatous polypo-
sis [39]), as well as at 30 μM, a lower than EC50 concentra-
tion.
Celecoxib activated p53
We verified that stable transfection of U87MG cells with
oncoprotein E6 inhibited p53 protein expression (Figure
2A). In U87MG and LN229 cells (both with functional
p53), we analysed whether celecoxib activated p53 with
resultant p53-dependent anti-proliferative effects. West-
ern blot analysis showed that celecoxib enhanced total
p53 protein expression in a concentration-dependent
manner in U87MG and LN229 cells (Figure 2B). Activa-
tion of p53 by celecoxib was verified by translocation of
p53 from cytoplasm into nucleus when U87MG cells were
treated with celecoxib (8 and 30 μM, 18 hours treatment)
compared with untreated controls (Figure 2C).
Celecoxib caused p53-dependent G1 cell cycle arrest, 
accompanied with p21 activation
We analysed the human glioblastoma cells to determine
whether activation of p53 by celecoxib led to cell cycle
arrest. We synchronised glioblastoma cells in serum-free
media for 48 hours, with resultant 75.7 ± 1.6% of U87MG
cells and 82.3 ± 1.7% of U87MG-E6 cells, being arrested
at G0 phase. Thereafter, starved cells were released from
serum-free condition and treated with celecoxib for 18
hours in medium containing 10% FBS. Following release
from starvation, celecoxib activated p53, as shown by the
enhanced total p53 expression in U87MG cells. Addition
of PFT inhibited celecoxib-induced p53 expression (Fig-
ure 3A). At 18 hours following release from starvation, cell
cycle analysis showed that 47.8 ± 2.7% of untreated
U87MG cells remained in G1 phase. Celecoxib (in a con-
centration-dependent manner) prevented U87MG cells
from entering S-phase, resulting in a significantly greater
population of cells at G1-phase, compared to untreated
controls (P < 0.05, Figure 3B, 3D). There was reciprocal
reduction of celecoxib-treated U87MG cells in S- and
G2M-phases, compared to untreated controls.
To establish whether the celecoxib-induced G1 cell cycle
arrest in U87MG cell was dependent on p53, we analysed
the effect of celecoxib (8 and 30 μM) on cell cycle progres-
sion of U87MG-PFT and U87MG-E6 cells. PFT by itself,
prevented U87MG cells from entering S-phase, as demon-
strated by the greater population of cells at G1-phase (58.7
± 2.3%) compared to the population of untreated U87MG
cells at G1 phase (47.8 ± 2.7%; Figure 3D). PFT (25 μM),
being a transient and reversible inhibitor of p53, is less
efficient in blocking elevated amount of p53 (such as
when p53 expression was increased during serum starva-
tion, data not shown), resulting in a greater population of
U87MG-PFT cells at G1phase compared to the population
of U87MG cells at G1 phase. In parallel, Xu et al. (2005)
demonstrated that PFT (20 μM) had no effect on cell cycle
progression of U87MG cells [40]. Addition of celecoxib to
PFT-treated U87MG cells did not affect the cell cycle pro-
gression when p53 was inhibited (P > 0.05, Figure 3B,
3D), suggesting a p53-dependent celecoxib-induced G1
cell cycle arrest in U87MG cells. Continuous inactivation
of p53 by E6 in U87MG-E6 cells reduced the proportion
of cells at G1 phase (29.5 ± 3.3%), compared with the
population of U87MG cells at G1 phase (47.8 ± 2.7%).
This is in accord with the functional role of p53 in arrest-
ing cells at G1 phase, as was previously shown [41]. Simi-
lar to U87MG-PFT cells, celecoxib had no significant effect
on U87MG-E6 cell cycle progression (P > 0.05, Figure 3B,
3D), thus confirming a p53-mediated G1 cell cycle arrest
by celecoxib in U87MG glioblastoma cells.
82.4 ± 0.9% of LN229 and 51.0 ± 3.7% of U373MG cells
were arrested at G0/1 phase, following 48 hours of starva-
tion in serum-free media. At 18 hours following treatment
(in media containing 10% FBS), celecoxib prevented
LN229 cells from entering S-phase and concentration-
dependently increased the percentage population of
LN229 cells in G1 phase, compared with untreated con-
trols (P < 0.05, Figure 3C, 3E). Celecoxib had no signifi-Page 4 of 16
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Effect of celecoxib on p53 protein expression and localisationFigure 2
Effect of celecoxib on p53 protein expression and localisation. U87MG and U87MG-E6 cells were analysed for basal 
p53 expression (A). U87MG and LN229 cells were treated with celecoxib (18 hours), followed by immunoblotting for detec-
tion of p53. β-actin was used as loading controls. p53 expression is presented normalised over β-actin of same samples. C, con-
trols; 8 and 30, treated with celecoxib 8 and 30 μM, respectively (B, n = 4–5). Representative images of celecoxib-treated (18 
hours) U87MG cells immunostained with anti-p53 FITC and DAPI are shown (C, n = 3).
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Effect of celecoxib on p53-dependent cell cycle progressionFigure 3
Effect of celecoxib on p53-dependent cell cycle progression. Cells were synchronised in serum-free medium for 48 
hours and then treated with celecoxib (8 and 30 μM) in medium containing 10% FBS for 18 hours. In some cases, U87MG cells 
were pre-treated with PFT (25 μM) prior to celecoxib treatment. Cells were collected for protein extraction and cell cycle 
analysis. Following release of cells from starvation, the effect of celecoxib on p53 protein expression in U87MG and PFT-
treated U87MG cells is shown (A). For cell cycle analysis, cells were fixed, stained with propidium iodide and analysed by flow 
cytometry. Representative histograms of cell cycle progression (B-C) and quantitative analysis of percentage gated cells at G1, 
S and G2M phases (D-E) are shown. All values are expressed as mean ± S.E.M, n = 5–8.
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0.05, Figure 3C, 3E). These findings parallel the effect of
celecoxib that induces G1 cell cycle arrest in U87MG cells,
but not U87MG-E6 or U87MG-PFT cells, thus verifying an
induction of p53-dependent G1 cell cycle arrest by
celecoxib in human glioblastoma cells.
Induction of G1 cell cycle arrest following DNA damage is
dependent on up-regulation of CDK inhibitors such as
p21, a direct transcriptional target of p53 that is strongly
induced by DNA damage in cells expressing wild-type p53
[42]. We analysed whether p53-dependent G1 cell cycle
arrest caused by celecoxib was mediated via p21 activa-
tion. Under the same synchronised cell condition where
celecoxib induced p53-dependent G1 cell cycle arrest, our
data showed that celecoxib caused a concentration-
dependent increased in p21 mRNA expression in U87MG
cells, but not in U87MG-E6 cells where p53 expression
was depleted (Figure 4A). We verified these findings by
immunocytochemistry, which demonstrated nuclear
induction of p21 when U87MG cells were treated with
celecoxib (8 and 30 μM; Figure 4B). In U87MG-E6 cells,
celecoxib (8 and 30 μM) caused no significant changes in
p21 mRNA expression (Figure 4A) and nuclear p21 pro-
tein level (Figure 4B). These data suggest that celecoxib-
induced p53-dependent G1 cell cycle arrest is mediated by
p21 activation in U87MG cells.
Celecoxib induced p53-dependent cell autophagy but not 
apoptosis
We investigated the functional consequences of celecoxib
on programmed cell death type I (apoptosis) and type II
(autophagy), whether celecoxib inhibited glioma prolifer-
ation by p53-dependent induction of apoptosis or
autophagy. In addition to inducing apoptosis, p53 is also
known to protect cells from apoptosis and necrotic cell
death [43]. As such, inhibition of p53 by PFT and E6 sig-
nificantly increased the apoptosis level of U87MG-PFT
and U87MG-E6 cells, respectively, compared to the basal
apoptosis level of U87MG cells (P < 0.05, Figure 5B). Sim-
ilarly, the basal apoptosis level of U373MG cells (with
mutant p53) was greater than LN229 and U87MG cells
(both with functional p53; Figure 5B), as was also shown
by others [43]. Regardless of p53 status in the glioma cells,
celecoxib (8 and 30 μM, 72 hours treatment) did not
cause any significant change in apoptosis population of
U87MG, U87MG-PFT, U87MG-E6 and U373MG cells (P
> 0.05, Figure 5). Celecoxib concentration-dependently
increased apoptosis population of LN229 cells, from 2.4
± 0.4% (controls) to 3.2 ± 0.5% (8 μM, P > 0.05) and 4.0
± 0.5% (30 μM; P < 0.05, Figure 5C) of total cell popula-
tion. At 72 hours treatment, celecoxib (30 μM) signifi-
cantly inhibited the survival of LN229 cells to a remaining
viable population of 38.9 ± 7.4% (see Figure 1F; P < 0.05,
Student's t-test). The small 1.6% increment in apoptosis
level of LN229 cells following 72 hours celecoxib treat-
ment (30 μM) suggests apoptosis as a minor mechanism
to mediate the anti-proliferative response induced by
celecoxib in LN229 cells. The non-significant change in
apoptosis level following celecoxib treatment in U87MG,
U87MG-PFT, U87MG-E6 and U373MG cells further dem-
onstrates that an alternative major cell death mechanism
(such as autophagy) is involved in the anti-proliferative
response induced by celecoxib in human glioblastoma
cells.
To analyse autophagy, we used acridine orange to stain
acidic vesicular organelles (AVOs) that include
autophagic vacuoles [44]. In untreated U87MG cells, the
cytoplasm and nucleolus fluoresced bright green and dim
red. Celecoxib treatment induced the development of
AVOs in U87MG cells, as shown by the concentrated flu-
orescence bright red acidic compartments (Figure 6A).
The intensity of red fluorescence is proportional to the
degree of acidity and/or volume of the cellular acidic com-
partment [45]. An increase in the intensity of red fluores-
cence was observed in U87MG cells treated with
increasing concentrations of celecoxib (from 8 to 30 μM,
Figure 6A–B). When the AVO staining of celecoxib-treated
U87MG cells was quantified, we demonstrated that 14.0
± 3.9% and 18.4 ± 5.7% of total cells were significantly
stained with acridine orange following celecoxib treat-
ment (8 and 30 μM, respectively), compared with
untreated controls (3.8 ± 0.0%; P < 0.05, Figure 6C). Inhi-
bition of p53 by PFT significantly induced autophagy of
U87MG cells (P < 0.05, Figure 6C; [46]). Addition of
celecoxib had no significant effect on the acridine orange
staining of U87MG-PFT cells (P > 0.05, Figure 6C). In
U87MG-E6 cells with reduced level of p53, development
of AVOs following celecoxib treatment was not obvious
(by microscopic observation, Figure 6A) and statistically
non-significant (by FACS analysis; P > 0.05, Figure 6B,
6C). We verified the celecoxib-induced p53-dependent
autophagy in U87MG cells by the changes in expression of
light chain 3 (LC3)-II, an autophagosome-specific protein
that is recruited to the autophagosome membrane during
autophagy [47]. Celecoxib (8 and 30 μM) further induced
cleavage of LC3 (conversion from LC3-I to LC3-II) in
U87MG cells, in parallel with the development of AVOs
following celecoxib treatment. Celecoxib (8 and 30 μM)
had no effect on the level of LC3-II expression in U87MG-
PFT and U87MG-E6 cells (Figure 6E).
In LN229 cells (with functional p53), celecoxib (8 and 30
μM, 72 hours treatment) significantly induced the devel-
opment of AVOs (P < 0.05, Figure 6D), as shown by the
significant increased of celecoxib-treated acridine orange-
stained cells (14.8 ± 8.7% [8 μM] and 19.7 ± 7.4% [30
μM]), compared with controls (2.9 ± 1.8%). The level of
autophagy induction by celecoxib in LN229 cells (4.0–5.8Page 7 of 16
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induction in celecoxib-treated U87MG cells, which
express functional p53. Celecoxib-induced autophagy
response in LN229 cells was supported by the increased
expression of LC3-II (Figure 6F). Celecoxib had no signif-
icant effect on the development of AVOs, or the level of
LC3-II expression in U373MG cells, which contain
mutant p53 (Figure 6D, 6F). These findings suggest that
celecoxib induced p53-dependent autophagy rather than
apoptosis in glioblastoma cells.
Celecoxib induced DNA damage and inhibited DNA 
synthesis
To investigate the upstream events preceding p53 activa-
tion following celecoxib treatment, we analysed the effect
of celecoxib on DNA damage by Comet assays under non-
denaturing condition, where induction of comet tails sug-
gests DNA double-strand breaks. Following 5 and 18
hours of treatment, celecoxib (8 and 30 μM) significantly
increased comet tail moments of U87MG cells (P < 0.05,
Figure 7A). Normalised mean tail moments by celecoxib
Effect of celecoxib on p21 mRNA expression and protein localisationFigure 4
Effect of celecoxib on p21 mRNA expression and protein localisation. Cells were synchronised in serum-free 
medium for 48 hours and then treated with celecoxib (8 and 30 μM) in medium containing 10% FBS for 18 hours. Total RNA 
was extracted from celecoxib-treated cells, followed by RT-PCR using p21 primers. p21 mRNA expression is presented nor-
malised over GAPDH of same samples (A, n = 3–5). Representative images of celecoxib-treated cells immunostained with anti-
p21 FITC and DAPI are shown (B, n = 3).Page 8 of 16
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Effect of celecoxib on cell apoptosisFigure 5
Effect of celecoxib on cell apoptosis. Cells were treated with celecoxib (8 and 30 μM) for 72 hours. In some cases, 
U87MG cells were pre-treated with PFT (25 μM) prior to celecoxib treatment. Cells were collected and stained with Annexin 
V-FITC and propidium iodide, followed by FACS analysis. Percentage population of early apoptosis (lower right quadrant) and 
late apoptosis (upper right quadrant) in celecoxib-treated U87MG and U87MG-E6 cells, stained with Annexin-FITC and pro-
pidium iodide are shown (A). Summary quantitative analyses of total apoptosis population following celecoxib treatment are 
presented (B-C). Values are expressed as mean ± S.E.M., n = 3–6. *P < 0.05, significantly different from respective controls (1-
way ANOVA, Dunnett's test). #P < 0.05, significantly different between PFT-treated and -untreated U87MG cells (Mann-Whit-
ney U-test).
Molecular Cancer 2009, 8:66 http://www.molecular-cancer.com/content/8/1/66(30 μM) at 5 and 18 hours were 259 ± 37% and 372 ±
67%, respectively, of untreated controls (Figure 7A). The
effect of celecoxib on DNA synthesis was assessed by
incorporation of 3H-thymidine into DNA during cellular
S-phase. Celecoxib (8 and 30 μM, 5 hours treatment) con-
centration-dependently inhibited DNA synthesis of
U87MG cells (by 25–36% vs. controls, P < 0.05, Figure
7B), corresponding with celecoxib-induced DNA damage.
Discussion
Therapeutic targeting of glioblastoma cells with selective
COX-2 inhibitors such as celecoxib has demonstrated
Effect of celecoxib on p53-dependent autophagyFigure 6
Effect of celecoxib on p53-dependent autophagy. Cells were treated with celecoxib (8 and 30 μM) for 72 hours. In some 
cases, U87MG cells were pre-treated with PFT (25 μM) prior to celecoxib treatment. Cells were collected and stained with 
acridine orange. Representative images of acridine orange-stained celecoxib-treated cells captured by confocal microscopy (A) 
and analysed by FACS (B) are shown. Summary quantitative analyses of acridine orange-stained cell populations following 
celecoxib treatment are presented (C-D). Values are expressed as mean ± S.E.M., n = 3–9. *P < 0.05, significantly different 
from respective controls (1-way ANOVA, Dunnett's test). #P < 0.05, significantly different between PFT-treated and -untreated 
U87MG cells (Mann-Whitney U-test). Protein was extracted from celecoxib-treated (72 hours) cells and analysed for expres-
sion of the autophagy marker, LC3. Representative blots of LC3 isoforms LC3-I and LC3-II proteins in celecoxib-treated cells 
are shown (E-F, n = 3). β-actin was used as loading control.Page 10 of 16
(page number not for citation purposes)
Molecular Cancer 2009, 8:66 http://www.molecular-cancer.com/content/8/1/66potential [4,6-11]. However the underlying anti-prolifera-
tive mechanisms of COX-2 inhibitors remain unclear.
Understanding the mechanisms underlying the anti-
tumour properties of COX-2 inhibitors is needed for opti-
misation of therapeutic targeting by COX-2 inhibitors. In
this study, we analysed the p53-dependent anti-prolifera-
tive effect induced by a selective COX-2 inhibitor,
celecoxib in human glioblastoma cells. Our findings dem-
onstrate that celecoxib induced p53-dependent G1 cell
cycle arrest followed by autophagy, which are critical for
inhibiting growth and proliferation of glioblastoma cells
containing functional p53. We demonstrate insensitivity/
resistance of glioblastoma cells to the anti-proliferative
effect of celecoxib when p53 expression is inhibited/
Effect of celecoxib on DNA damage and DNA synthesisFigure 7
Effect of celecoxib on DNA damage and DNA synthesis. U87MG cells were treated with celecoxib (8 and 30 μM) and 
analysed for DNA damage by Comet assays, as shown by representative images and quantitated as comet tail moments (A, n = 
5–7). DNA synthesis is presented by incorporation of [3H]-thymidine/[14C]-thymidine in celecoxib-treated cells normalised 
over controls (B, n = 3–4). *P < 0.05, significantly different from respective controls (1-way ANOVA, Dunnett's test).Page 11 of 16
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when glioblastoma cells express functional p53. Growth
inhibition mediated via p53-dependent [33,34,48] and
p53-independent [16,49,50] mechanisms have been
reported with non-selective and selective COX-2 inhibi-
tors in studies of tumour and non-tumour cells. In brain
tumours, this finding is the first to report a p53-depend-
ent anti-glioblastoma effect of a selective COX-2 inhibi-
tor, which supports selective usage of celecoxib in human
glioblastomas with functional p53 for enhanced anti-
tumour responses.
p53 is a key molecule in DNA damage response, causing
inhibition of cell proliferation by induction of cell cycle
arrest, apoptosis/autophagy or senescence. The inhibitory
effect of p53 on cell proliferation is due to transcriptional
activation of target genes such as p21, GADD45, Bax, DR5
and PUMA [28]. In this study, inhibition of COX-2 by
celecoxib [51] activated p53 in human glioblastoma
U87MG cells, as demonstrated by translocation of p53
from cytoplasm to nucleus accompanied with accumula-
tion of total p53 expression. In line with our study, activa-
tion of p53 by COX inhibitors has also been
demonstrated in colon and oral cancer cells [33,34,52].
We investigated whether celecoxib-induced p53 activa-
tion is followed by cell cycle arrest, apoptosis or
autophagy in human glioblastoma cells. One study dem-
onstrated a tumour cell-type dependent effect of cell cycle
arrest and apoptosis following celecoxib treatment. Liu
and colleagues (2003) reported that celecoxib-induced
DNA damage led to G2M cell cycle arrest in mammary
(and not lung) cancer, but apoptosis in lung (and not
mammary) cancer cells [26]. The underlying mechanisms
for these differential celecoxib-induced functional
responses were not addressed. Our study in human gliob-
lastoma cells reveal that celecoxib-induced p53 activation
is followed by p53-dependent G1 cell cycle arrest and p21
activation. Celecoxib-induced G1 cell cycle arrest accom-
panied by increased p21 protein expression has been
reported in human cholangiocarcinoma [12], colorectal
[13,17], hepatocellular [35] and prostate cancer cells [14].
While apoptosis is considered a major anti-proliferative
mechanism of celecoxib [9,13-15,17,26], our findings
show that induction of p53-dependent G1 cell cycle arrest
by celecoxib is followed by p53-dependent cell autophagy
and not apoptosis. It should be noted that higher concen-
trations of celecoxib (40–100 μM) induce apoptosis
[9,13-15,17,26]. The celecoxib concentrations (40–100
μM) are 4 to 11-fold greater than 8 μM, the human plasma
concentration of celecoxib after consumption of 800 mg/
kg per day [39] and the concentration that is presently
used in this study. Mazzanti et al. (2009) recently showed
that celecoxib (10 and 20 μM) induces apoptosis, but
lower concentrations of celecoxib (at 2.5 and 5 μM)
induce autophagy in hepatocellular carcinoma cells that
are cultured in serum-free medium [35]. The sensitivity of
tumour cells to celecoxib-induced cellular apoptosis or
autophagy is likely to be concentration- or tumour type-
dependent. The role of p53 in autophagy remains contro-
versial with studies suggesting activation of p53, as well as
inhibition of p53, as inductive of autophagy [46]. In our
study, induction of autophagy by celecoxib in glioblast-
oma cells is p53-dependent, as shown by the autophagy
induction only in celecoxib-treated glioblastoma cells
with high (and not low) functional level of p53. In con-
trast, Mazzanti et al. (2009) reported that induction of
autophagy by celecoxib (2.5 and 5 μM) is mediated by P-
glycoprotein and Bcl2 via a p53-independent mechanism.
The role of autophagy in cancer development is complex,
as it has been implicated in both tumour survival and
tumour cell death [53]. Induction of cell cycle arrest pre-
ceding autophagy induction inhibits tumor growth [54].
Our results support the induction of p53-dependent G1
cell cycle arrest, followed by autophagy as a mechanism
for celecoxib to prevent glioma cell survival. Induction of
p53-dependent autophagy independent of apoptosis
should be considered as one of the underlying anti-prolif-
erative mechanisms of COX-2 inhibitors, celecoxib in par-
ticular, in various tumours.
We investigated the 'up-stream' mechanisms preceding
p53 activation in U87MG cells treated with celecoxib. We
found that celecoxib (8 and 30 μM) induced DNA dam-
age, accompanied with inhibition of DNA synthesis in
U87MG cells, which led to p53-induced G1 cell cycle arrest
and autophagy events. These findings of celecoxib-
induced DNA damage followed by p53-dependent G1 cell
cycle arrest and autophagy are clinically relevant since low
concentration of celecoxib (8 μM) are attainable in
human serum [39]. In cancer cells, DNA damage was
induced following celecoxib treatment (at high concentra-
tions of 50 and 100 μM) in murine lung (A549) and
mammary (MCa-35) cancer cells [26], and by the non-
selective COX inhibitor aspirin in HT-29 human colon
carcinoma [25]. Activation of DNA damage-p53 signal-
ling by COX-2 inhibitors has not been reported. One
study proposes induction of DNA damage by the COX
inhibitor R-flurbiprofen following the observation that R-
flurbiprofen increases p53 (Ser 15) phosphorylation in
colon cancer cells, but this has yet to be verified [33]. Our
study demonstrates that selective COX-2 inhibition by
celecoxib induces DNA damage and inhibits DNA synthe-
sis, resulting in p53 activation and subsequent anti-prolif-
erative effects in glioblastoma cells. The mechanisms
underlying celecoxib-induced DNA damage remain
unclear and are beyond the scope of this study. Whilst
inhibition of COX-2 expression is reported to reduce gen-
eration of reactive oxygen species and prevent DNA dam-
age, recent studies show that COX-2 inhibitors celecoxibPage 12 of 16
(page number not for citation purposes)
Molecular Cancer 2009, 8:66 http://www.molecular-cancer.com/content/8/1/66[55] and sulindac [56], induce reactive oxygen species to
mediate anti-tumour responses. Seo et al. (2007) also
showed that induction of reactive oxygen species by sulin-
dac was accompanied by phosphorylation of p53 (Ser 15)
and accumulation of p53 in human multiple myeloma
cells [56]. It is possible that celecoxib induces reactive oxy-
gen species, followed by activation of DNA damage-p53
signalling to mediate anti-glioblastoma effects, but this
requires further investigation.
Conclusion
Our study reveals an important underlying mechanism of
celecoxib-mediated inhibition of glioblastoma cell
growth, by induction of DNA damage leading to p53-
dependent G1 cell cycle arrest and autophagy, but not
apoptosis. These results highlight the importance of p53
for enhanced anti-glioblastoma response by celecoxib.
With the clinical relevant concentration of celecoxib used
in this study, the present findings support potential clini-
cal application of celecoxib to improve therapy of gliob-
lastoma multiforme patients.
Methods
Cell culture and drug treatment
Human glioblastoma cells U87MG, U373MG, LN229
(American Type Culture Collection, Rockville, MD) and
U87MG-E6 (U87MG cells transfected with human papil-
lomavirus E6 oncoprotein, kindly provided by Russell O.
Pieper, UCSF Comprehensive Cancer Centre, San Fran-
cisco, CA) were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with fetal bovine serum
(FBS, 10%), nonessential amino acids (100 μM), sodium
pyruvate (1 mM), streptomycin (100 μg/ml) and penicil-
lin (100 U/ml, Gibco BRL, Grand Island, NY) at 37°C in
an atmosphere containing 5% CO2.
Celecoxib (Pfizer Pharmacia, New York, NY) and pifit-
hrin-α (PFT, Sigma, St. Louis, MO) was prepared as 100
mg/ml and 10 mg/ml stock in dimethyl sulfoxide
(DMSO; Sigma), respectively. Stock solutions were
diluted to required concentrations with culture medium
on the day of treatment. U87MG cells were treated with
PFT (U87MG-PFT) for 30 minutes prior to celecoxib treat-
ment. Vehicle DMSO was used as drug replacement in
experimental controls. The final DMSO concentration did
not exceed 0.15% (v/v). All experiments were performed
in accordance with guidelines approved by the Institu-
tional Review Board of National Cancer Centre, Singa-
pore.
Cell viability assay
In 96-well plates, cells were treated with increasing con-
centrations of celecoxib to identify dose-dependent viabil-
ity of U87MG, U87MG-E6, U87MG-PFT, LN229 and
U373MG cells. In some cases, U87MG cells were pre-
treated with PFT (25 μM) for 30 minutes prior to celecoxib
treatment. After 24 and 72 hours, cells were stained with
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT, 1 mg/ml), incubated for 4 hours at 37°C,
lysed with lysis buffer (N, N-dimethyl formamide, 50%;
sodium dodecyl sulphate, 20%) and absorbance meas-
ured at 570 nm. Readings of celecoxib-treated cells were
normalised against DMSO-treated controls.
Western blot analysis
Cells treated with DMSO or celecoxib (8 and 30 μM) were
lysed and protein quantitated by Bradford assays (Bio-Rad
Laboratories, Hercules, CA). Equal amounts of protein
were separated in SDS-polyacrylamide gels and trans-
ferred onto nitrocellulose membranes (Amersham Bio-
sciences). Membranes were blocked with 5% skim milk,
incubated overnight (4°C) with monoclonal anti-p53
(DO-1, 1:500, Santa Cruz Biotechnology, Santa Cruz, CA)
or rabbit polyclonal anti-LC3 (1:500, Santa Cruz Biotech-
nology), followed by horseradish peroxidase-conjugated
secondary antibodies (Amersham Biosciences). Protein
bands were visualised with ECL plus chemiluminescence
kit (Amersham Biosciences). For loading controls, mem-
branes were stripped and re-probed with horseradish per-
oxidase-conjugated anti-β-actin (Santa Cruz
Biotechnology).
Immunocytochemistry
Celecoxib-treated (0, 8 and 30 μM) cells (grown on cover
slips) were fixed and permeabilised in 0.2% Triton X-100.
After wash, cells were blocked with 5% BSA, incubated
with specific antibodies against p53 (1:50, Neomarkers,
Fremont, CA) or p21 (1:100, Santa Cruz Biotechnology)
for 1 hour at room temperature, followed by incubation
with anti-mouse FITC-conjugated secondary antibodies
(1:200, Molecular Probes). Cover slips were mounted
with VectaShield Mounting Medium containing DAPI
(Vecta Laboratories, Burlingame, CA). Images were
viewed under a Laser Scanning Microscope and images
captured using software LSM510 (Zeiss, Germany).
Cell cycle analysis and p21 mRNA expression
Cells were synchronised at Go phase in serum-free
medium for 48 hours, followed by celecoxib treatment (0,
8 and 30 μM) in medium containing 10% FBS for 18
hours. In some cases, U87MG cells were pre-treated with
PFT (25 μM) for 30 minutes prior to celecoxib treatment.
For cell cycle analysis, collected cells were fixed overnight
with ice-cold ethanol (75%), stained with propidium
iodide (5 μg/ml, Sigma) supplemented with 100 μg/ml
RNase (Sigma), and then analysed with flow cytometry
using CellQuest Pro (BD Biosciences, San Jose, CA) for
10,000 events. For p21 mRNA analysis, total RNA was
extracted from celecoxib-treated cells with Tri-Reagent
(Molecular Research Centre, Cincinnati, OH). 1 μg totalPage 13 of 16
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Transcription system (Promega Corporation, Madison,
WI). PCR was performed with specific primers for p21
(forward: 5'-CAGCATGACAGATTTCTACCAC-3', reverse:
5'-CCAGGGTATGTACATGAGGAG-3') and GAPDH (for-
ward: 5'-GGAAGGTGAAGGTCGGAGTC-3', reverse: 5'-
GTCTTCTGGGTGGCAGTGAT-3') at the following condi-
tions: 94°C, 55°C and 72°C at 30 seconds each tempera-
ture for 30 cycles.
Apoptosis and autophagy assays
Cells were treated with DMSO or celecoxib (8 and 30 μM)
for 72 hours. In some cases, U87MG cells were pre-treated
with PFT (25 μM) for 30 minutes prior to celecoxib treat-
ment. For apoptosis assays, trypsinised cells were incu-
bated with FITC-conjugated Annexin V (BD Biosciences)
and propidium iodide (5 μg/ml). 10,000 events were ana-
lysed for apoptosis by FACS with CellQuest Pro software.
For autophagy assays, celecoxib-treated cells were stained
with acridine orange (1 μg/ml, Sigma) for 15 mins at
37°C. Trypsinised cells were re-suspended in phenol red-
free growth media (Gibco BRL) and 10,000 events were
analysed by FACS with CellQuest Pro software. Acridine
orange-stained cells grown on cover slips were viewed
under a Laser Scanning Microscope and images captured
using software LSM510.
Comet assays and 3H-thymidine incorporation assays
DNA damage was analysed by Comet assays as follows:
Sub-confluent cells were treated with DMSO or celecoxib
(8 and 30 μM) for 5 and 18 hours. Cells were mixed with
0.5% low melting point agarose and allowed to solidify
on slides. Slides were immersed in lysis buffer, electro-
phoresis in tris-base buffer, stained with SYBR Green 1
(Trevigen, Gaithersburg, MD) and analysed with fluores-
cence microscopy. DNA damage, characterised by forma-
tion of comet tails, was quantitated by tail moments
(multiplication of DNA tail migration from cell nucleus
with DNA content) using Comet Score Freeware (Tritek
Corporation, Summerduck, VA).
DNA synthesis was quantified with 3H-thymidine incor-
poration assays as follows: Sub-confluent cells were
labeled with [methyl-14C]-thymidine (Amersham Bio-
sciences, Buckinghamshire, UK) overnight, followed by
celecoxib treatment (8 and 30 μM, 5 hours). After wash,
cells were incubated with medium containing [methyl-
3H]-thymidine (Amersham Biosciences) for 20 minutes,
followed by 5% trichloroacetic acid and then 100% etha-
nol. Cells were air-dried, lysed in 1% sodium dodecyl sul-
phate and 10 mM NaOH, and subsequently the
radioactivity measured with a liquid scintillation counter
(Wallac, Turku, Finland). A control sample labelled with
[methyl-14C]-thymidine alone was included to determine
[methyl-14C]-thymidine signal spillover into [methyl-3H]-
thymidine channel. DNA synthesis was presented as a per-
centage of [methyl-3H]-thymidine/[methyl-14C]-thymi-
dine ratio in celecoxib-treated cells over controls.
Statistical analysis
All values are presented as mean ± standard error of mean
(S.E.M.) and n indicates number of independent experi-
ments. The concentration-dependent effect of celecoxib
on viability of glioblastoma cells was analysed by 2-way
analysis of variance (2-way ANOVA). The effect of
celecoxib on DNA damage, DNA synthesis, cell cycle pro-
gression, autophagy and cell apoptosis were analysed by
1-way ANOVA, followed by Dunnett's test (control vs.
celecoxib, 8 or 30 μM). The effect of PFT on cell apoptosis
and autophagy in U87MG cells was analysed by Mann-
Whitney U-test. A P value of less than 0.05 was considered
to be significant. GB-STAT (Dynamic Microsystems, Silver
Springs, MD) statistical package was used in all calcula-
tions.
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